|
|
|
|
Small Stocks, Big Money™
|
|
Weekly Newsletter
|
|
|
|
|
|
|
|
ASP Isotopes Reaches Commercial Breakthrough with First Isotope Shipments, Eyes $300M EBITDA by 2030
ASP Isotopes (Nasdaq: ASPI) has officially transitioned from R&D to commercial operations, successfully shipping initial batches of Ytterbium-176 and Silicon-28—unlocking a potential $50–70M revenue stream over 2026–2027. With three enrichment plants now operational and plans for four more underway, the company is positioning itself as a global leader in critical isotopes and nuclear fuels. Backed by strong demand across energy, medicine, and semiconductors and bolstered by the Renergen merger and upcoming Quantum Leap Energy IPO, ASPI aims to generate $300M+ in EBITDA by 2030.
|
|
|
|
Gorilla Technology Lands Landmark Multi-Million Dollar Deal to Scale World's First Fully Deployed 5G Lawful Interception Platform
Gorilla Technology (Nasdaq: GRRR) has secured a transformative, multi-year contract worth tens of millions to expand its 5G-native Lawful Interception platform—the first of its kind—across Asia-Pacific’s largest criminal investigation bureau. This AI-powered, telecom-grade solution enables real-time, high-volume intelligence gathering and positions Gorilla as a global leader in next-gen security infrastructure for national agencies and Tier-1 telecoms.
|
|
|
|
|
Lantern Pharma Gains FDA Alignment on Pediatric Brain Cancer Trial, Paving Way for Q1 2026 Launch
Lantern Pharma (Nasdaq: LTRN) has successfully completed a Type C meeting with the FDA, securing key regulatory guidance to advance its AI-driven pediatric CNS cancer trial, including a dedicated ATRT cohort, under its Starlight Therapeutics subsidiary. The trial will evaluate LP-184/STAR-001 in combination with spironolactone, supported by Rare Pediatric Disease and Orphan Drug designations, and marks a major step toward delivering precision oncology to children with aggressive brain tumors.
|
|
|
|
|
|
|
NioCorp’s Elk Creek Project Gains Strategic Momentum as Three Core Minerals Elevated to Top U.S. Critical List
NioCorp (Nasdaq: NB) is gaining ground as a strategic national asset with niobium, dysprosium, and terbium—key elements in its Elk Creek Project—now ranked among the U.S. government’s highest-priority critical minerals. Niobium alone poses the second-largest threat to U.S. GDP if foreign supply is disrupted, underscoring the urgency of developing domestic production. With all major project minerals officially designated as critical, NioCorp positions Elk Creek as one of America’s most vital, fully permitted critical mineral resources.
|
|
|
|
|
XORTX Begins IND Prep for XORLO™ in Gout Program, Advancing Toward NDA Filing
XORTX Therapeutics (Nasdaq: XRTX) has initiated Investigational New Drug (IND) preparation for XORLO™, its proprietary oxypurinol formulation targeting gout, a condition affecting over 9 million Americans. Supported by FDA guidance and in partnership with CRO Allucent, the IND will include a pharmacologic study in fed vs. fasted states, paving the way for a future NDA. XORLO™ aims to address the treatment gap for patients intolerant to existing xanthine oxidase inhibitors, offering a differentiated, potentially safer option in a growing global gout market.
|
|
|
Recent News
|
RedChip TV
|
|
|
|
Learn why Lake Street Capital gives Lantern Pharma (Nasdaq: LTRN) a buy rating and $25 price target
|
|
|
|
|
|
Inside Lantern Pharma’s Harmonic™ Trial: A Targeted Lung Cancer Approach with LP-300
|
|
|
|
|
|
|
|
|
|
Unlock Smarter Investing with RedChat
|
|
|
Tired of sifting through endless filings? Let RedChat do the heavy lifting. Get real-time, data-driven insights on over 2,000 small-cap stocks—instantly. Save time, make informed decisions, and stay ahead of the market.
|
|
Access RedChat now, free of charge.
|
|
|
|
|
Recent Research Coverage Updates
| Company |
Rating |
Price Target |
Firm |
Report Date |
| Greenwich LifeSciences (Nasdaq: GLSI) |
Buy |
$45 |
Noble |
August 20, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$7 |
HC Waingwright |
August 12, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$4 |
Maxim |
August 12, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$4 |
Maxim |
August 12, 2025 |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$16 |
D Boral |
July 29, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$7.5 |
Northland Securities |
July 23, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$4 |
Titan Partners |
July 17, 2025 |
| NioCorp (Nasdaq: NB) |
Buy |
$5 |
Maxim |
July 10, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$7 |
H.C. Wainwright |
July 9, 2025 |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$16 |
D Boral |
July 9, 2025 |
| NioCorp (Nasdaq: NB) |
Buy |
$4 |
HC Wainwright |
July 2, 2025 |
| Alliance Entertainment (Nasdaq: AENT) |
Buy |
$10 |
Maxim |
July 1, 2025 |
| Lantern Pharma (Nasdaq: LTRN) |
Buy |
$25 |
Lake Street |
June 17, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$4 |
Craig Hallum |
June 5, 2025 |
| Creative Medical (Nasdaq: CELZ) |
Buy |
$8 |
Roth |
June 4, 2025 |
| Alliance Entertainment (Nasdaq: AENT) |
Buy |
$8 |
ThinkEquity |
June 2, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$7.25 |
Ascendiant Capital |
April 20, 2025 |
| Enlivex Therapeutics (NASDAQ: ENLV) |
Buy |
$7 |
H.C. Wainwright |
March 24, 2025 |
| BioVie (Nasdaq: BIVI) |
Buy |
$6 |
Brookline |
March 18, 2025 |
| Lantern Pharma (Nasdaq: LTRN) |
Buy |
$15 |
ThinkEquity |
March 17, 2025 |
| Jupiter Neurosciences (Nasdaq: JUNS) |
Buy |
$30 |
Greenridge Global |
March 6, 2025 |
| Fathom Holdings (NASDAQ: FTHM) |
Buy |
$3.75 |
Roth |
March 3, 2025 |
| XORTX Therapeutics (Nasdaq: XRTX) |
Buy |
$14 |
AGP |
February 25, 2025 |
| Enlivex Therapeutics (NASDAQ: ENLV) |
Buy |
$13 |
D. Boral |
February 7, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$18 |
Northland Capital Markets |
January 22, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$3 |
ThinkEquity |
January 13, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$27 |
Alliance Global Partners |
January 2, 2025 |
|
|
|
|
|
|
Small Stocks, Big Money™ Podcast
|
|
The podcast features in-depth interviews with CEO's from the top names in small-cap stocks, providing listeners with a unique perspective not found anywhere else.
|
|
Available on:
|
|
|
|
|
|
|
Upcoming Events
|
|
|
Nexalin Technology (NASDAQ: NXL)
4:15pm Eastern
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic.
|
|
|
|
XORTX Therapeutics (NASDAQ: XRTX)
4:15pm Eastern
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections.
|
|
|
|
Archived Events
|
|
|
RedChip Investor Webinar with Phoenix Motorcars (OTC: PEVMD)
4:15pm Eastern
Phoenix Motor, a pioneer in the electric vehicle ("EV") industry, designs, builds, and integrates electric drive systems and manufactures heavy duty transit buses and medium and light duty commercial EVs.
|
|
|
|
RedChip Investor Webinar with ASP Isotopes (NASDAQ: ASPI)
4:15pm Eastern
This exclusive event will provide investors with an opportunity to gain critical insights into ASP Isotopes' strategic initiatives and technological advancements.
|
|
|
|
Quote of the Week
|
" There is no passion to be found playing small - in settling for a life that is less than the one you are capable of living."
|
|
|
|
|
Order "Small Stocks, Big Money™ Today!
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
|
|
|
|
|
|
|
Lesson of the Week
Map your course for success with small-caps.
|
|
|
|
|
|
|
